Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pharmacokinetic and safety study of bimekizumab in pubertal children and adolescents with moderate to severe hidradenitis suppurativa
2023-505323-31-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in hidradenitis suppurativa (HS), sponsored by UCB. Planned start Jul 2025; status: authorised.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2023-505323-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505323-31-00.